台灣臨床試驗主持人資料庫|TPIDB

2016-12-01 - 2019-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double Blind, Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Naïve to Proteasome Inhibitors

Condition/Disease

Relapsed or Refractory Multiple Myeloma
Test Drug

Venetoclax (ABT-199)

Participate Sites
6Sites

Terminated5Sites

蕭樑材

Taipei Veterans General Hospital

Division of Hematology & Oncology

2019-01-01 - 2030-12-31

Phase III

ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)

Condition/Disease

Ovarian Cancer
Test Drug

Rucaparib ; Nivolumab

Participate Sites
14Sites

Terminated14Sites

王鵬惠

Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

2016-11-01 - 2022-10-28

Phase III

A Randomized, Double-blind, Placebo Controlled Phase III Study of Darolutamide (ODM-201) Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer

Condition/Disease

metastatic hormone-sensitive prostate cancer
Test Drug

BAY 1841788/ODM-201(Darlutamide)

Participate Sites
8Sites

Recruiting6Sites

黃逸修

Taipei Veterans General Hospital

馮思中

Linkou Chang Gung Medical Foundation

2017-02-01 - 2019-05-09

Phase III

Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent placement. (EdoxabaN Treatment versus VKA in patients with AF undergoing PCI ( ENTRUST-AF PCI)

Condition/Disease

Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement
Test Drug

Edoxaban (DU-176b)

Participate Sites
13Sites

Terminated11Sites

江晨恩

Taipei Veterans General Hospital

Division of Cardiovascular Diseases

2017-01-05 - 2019-12-31

Others

An Open-Label, Multicenter Phase Ib Study of The Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors

Condition/Disease

Solid Tumors
Test Drug

TECENTRIQ

Participate Sites
6Sites

Recruiting4Sites

Terminated1Sites

趙毅

Taipei Veterans General Hospital

陳仁熙

Linkou Chang Gung Medical Foundation

2017-12-19 - 2025-07-15

Phase III

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

Condition/Disease

DIFFUSE LARGE B-CELL LYMPHOMA
Test Drug

Polatuzumab vedotin

Participate Sites
6Sites

Recruiting5Sites

高志平

Taipei Veterans General Hospital

2018-07-24 - 2021-03-17

Phase III

A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients 55 Years or Older With Type 2 Diabetes Mellitus and Inadequate Glycemic Control

Condition/Disease

Type 2 Diabetes Mellitus
Test Drug

Sotagliflozin

Participate Sites
8Sites

Terminated8Sites

江晨恩

Taipei Veterans General Hospital

2017-11-15 - 2022-12-31

Phase III

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function

Condition/Disease

Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function
Test Drug

Sotagliflozin

Participate Sites
10Sites

Not yet recruiting1Sites

Terminated7Sites

江晨恩

Taipei Veterans General Hospital

Division of Cardiovascular Diseases

謝宜璋

Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2016-08-01 - 2021-01-10

Phase III

A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM-First)

Condition/Disease

Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Test Drug

Quizartinib (AC220)

Participate Sites
6Sites

Recruiting3Sites

Terminated3Sites

柯博伸

Taipei Veterans General Hospital

2015-11-01 - 2019-12-31

Phase III

A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events

Condition/Disease

Type 2 Diabetes Mellitus
Test Drug

Bexagliflozin Tablets

Participate Sites
9Sites

Terminated7Sites

江晨恩

Taipei Veterans General Hospital

賴文德

Kaohsiung Municipal Gangshan Hospital

未分科

Search Result

List